Monopar Therapeutics Inc. (MNPR) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 11 Buy, 2 Hold.
The consensus price target is $121.00 (low: $115.00, high: $125.00), representing an upside of 108.9% from the current price $57.92.
Analysts estimate Earnings Per Share (EPS) of $-1.38 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-411.23 vs est $-1.38 (missed -29785.9%). 2025: actual $-1.85 vs est $-1.68 (missed -10.1%). Analyst accuracy: 46%.
MNPR Stock — 12-Month Price Forecast
$121.00
▲ +108.91% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Monopar Therapeutics Inc., the average price target is $121.00, with a high forecast of $125.00, and a low forecast of $115.00.
The average price target represents a +108.91% change from the last price of $57.92.
Highest Price Target
$125.00
Average Price Target
$121.00
Lowest Price Target
$115.00
MNPR Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Monopar Therapeutics Inc. in the past 3 months
EPS Estimates — MNPR
46%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$411.23
vs Est –$1.38
▼ 99.7% off
2025
Actual –$1.85
vs Est –$1.68
▼ 9.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MNPR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
